Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646425 | 0.84 | ASAH1 (0.68) | ASAH1NPSR1HPGDALDH1A1ACER2 | |
| SCHEMBL17343770 | 0.82 | ASAH1 (0.89) | ASAH1NPSR1HPGDALDH1A1ACER2 | |
| SCHEMBL4987614 | 0.81 | ASAH1 (0.63) | ASAH1NPSR1HPGDALDH1A1ACER2 | |
| SCHEMBL18741947 | 0.80 | ASAH1 (0.76) | ASAH1NPSR1HPGDALDH1A1ACER2 | |
| SCHEMBL8335749 | 0.77 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2EPHX2SMN1; SMN2 | |
| SCHEMBL9848372 | 0.73 | ASAH1 (0.69) | ASAH1ALDH1A1ACER2EPHX2MEN1 | |
| SCHEMBL9848444 | 0.73 | ASAH1 (0.69) | ASAH1ALDH1A1ACER2EPHX2MEN1 | |
| SCHEMBL9843976 | 0.73 | NPSR1 (0.77) | ASAH1NPSR1HPGDALDH1A1ACER2 | |
| SCHEMBL25442176 | 0.73 | HPGD (0.57) | ASAH1HPGDPOLB | |
| SCHEMBL9848496 | 0.72 | ASAH1 (0.67) | ASAH1ALDH1A1ACER2EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | ASAH1 4414/4885NPSR1 3813/4885HPGD 3722/4885 |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CUL4B, CUL4A, UBQLN1 | ASAH1 4414/4885NPSR1 3813/4885HPGD 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.